Fetal and neonatal alloimmune thrombocytopenia

Download PDF Česká verzia

Authors: A. Neumann ¹; Z. Žižka ¹; M. Koucký ¹; H. T. Bolcková ²; P. Calda ¹
Authors place of work: Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha, přednosta prof. MUDr. A. Martan, DrSc. ¹; Ústav hematologie a krevní transfuze, Praha, přednosta prof. MUDr. P. Cetkovský, Ph. D., MBA ²
Published in the journal: Ceska Gynekol 2018; 83(6): 448-451
Category: Case Report

Summary

Objective:

This article shows our experience with fetal and neonatal alloimmune thrombocytopenia (FNAIT) on a particular patient and the difficulties we faced during the hospitalization.

Design:

Case report.

Setting:

Department of Obsterics and Gynecology 1st Faculty of Medicine, Charles University and General Faculty Hospital in Prague.

Methods:

Our experience with FNAIT therapy.

Results:

According to literature is recommended to use IVIG for FNAIT treatment. Women, who were treated by IVIG have better results, in comparison with women, who had no treatment at all. Our case is not confirming this statement, because first pregnancy of our patient terminated by IUFD, on the other hand second pregnancy was successful and she delivered healthy child.

Conclusion:

FNAIT is relatively rare disease, but if it appears, it can be dangerous for a fetus or for a new-born baby. In the worst case FNAIT can result in intracranial bleeding or prenatal death. There are limited preventive steps and available therapy produces uncertain results. The only partially accepted treatment substance is IVIG (intravenous immunoglobulins). Unfortunately, this therapy is very expensive and not accepted by some experts. This article shows our experience with FNAIT on a particular patient and the difficulties we faced during the hospitalization.

Keywords:

fetal and neonatal alloimmune thrombocytopenia, FNAIT, trombocytopenia, intracranial hemorrhage, misscarriage, IVIG

Zdroje

1. Berkowitz, RL., Lesser, ML., McFarland, JG., et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol, 2007, 110, p. 249–255. Epub 2007/08/02.

2. Bussel, JB., Berkowitz, RL., McFarland, JG., et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med, 1988, 319, p. 1374–1378. Epub 1988/11/24.

3. Calda, P., Břešťák, M., Fischerová, D. Ultrazvuková diagnostika v těhotenství a gynekologii. 2. kompletně přeprac. a rozšířené vyd. Praha: Aprofema, 2010. 496 s.

4. Čermáková, Z., Kovářová, P., Malušková, A. Optimalizace vyšetření protilátek proti trombocytům u těhotných žen po porodu. Čes Gynek, 2011, 76, 3, s. 239–242.

5. Daffos, F., Capella-Pavlovsky, M., Forestier, F. Fetal blood sampling via the umbilical cord using a needle guieded by ultrasound, report od 66 cases. Prenat Diag., 1983, 3, p. 271–277. Epub 1983/10/01

6. Dahl, J., Refsum, E., Ahlen, MT., et al. Unraveling the role of maternal anti-HLA class I antibodies in fetal and neonatal thrombocytopenia – antibody specificity analysis using epitope data. J reprod Immunol, 2017, 122, p. 1–9.

7. McQuilten, ZK., Wood, EM., Savola, H. A review of pathophysiology and current treatment for neonatal alloimmune thrombocytopenia (NAIT) and introducing the Australian NAIT registry. Aust N Z J Obstet Gynaecol, 2011, 51(3), p. 191–198.

8. Pacheco, LD., Berkowitz, RL., Moise, KJ. Jr., Brussel, JB. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol, 2011, 118(5), p. 1157–1163.

9. PROFNAIT. 2016. Available from: http://www.profnait.eu/

10. Santoso, S., Wihadmadyatami, H., Bakchoul, T., et al. Antiendothelial alphavbeta3 antibodies are a major cause of intracranial bleeding in fetal/neonatal alloimmune thrombocytopenia. Arterioscler Thromb Vasc Biol, 2016, 36, p. 1517–1524. Epub 2016/06/11.

11. Turner, ML., Bessos, H., Fagge, T., et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion, 2005, 45(12), p. 1945–1956.

12. Winkelhost, D., Oepkes, D., Lopriore, E. Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal managment strategies, Expert Rev Hematol, 2017, 10(8), p. 729–773.

13. Yougbare, I., Lang, S., Yang, H., et al. Maternal anti-platelet beta3 integrins impair angiogenesis and cause intracranial hemorrhage. J Clin Invest, 2015, 125, p. 1545–1556. Epub 2015/03/17